title: Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
abstract: The maximum tolerated dose of conformal radiation therapy delivered at 1.6 Gy bid is being assessed in patients with unresectable stage IIB-IIIB non-small cell lung cancer who have been treated with induction regimens consisting of carboplatin plus paclitaxel or carboplatin plus vinorelbine. Data from the early stages of this parallel phase I study show that the two induction regimens are similar in toxicity and that both induce partial responses in 45% of patients. Both regimens can be followed by conformal radiotherapy using an accelerated hyperfractionated schedule to a dose of at least 80 Gy without experiencing unacceptable toxicity. Key morbidity observed thus far has involved the esophagus. Further cohorts of patients will receive higher doses of conformal radiotherapy (in 6.4 Gy increments) until the maximum tolerated dose is reached.
authors.affiliation: Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514, USA. socinski@med.unc.edu
authors.forename: M A
authors.initials: MA
authors.lastname: Socinski
authors.forename: L B
authors.initials: LB
authors.lastname: Marks
authors.forename: J
authors.initials: J
authors.lastname: Garst
authors.forename: G S
authors.initials: GS
authors.lastname: Sibley
authors.forename: W
authors.initials: W
authors.lastname: Blackstock
authors.forename: A
authors.initials: A
authors.lastname: Turrisi
authors.forename: J
authors.initials: J
authors.lastname: Herndon
authors.forename: S
authors.initials: S
authors.lastname: Zhou
authors.forename: M
authors.initials: M
authors.lastname: Anscher
authors.forename: J
authors.initials: J
authors.lastname: Crawford
authors.forename: T
authors.initials: T
authors.lastname: Shafman
authors.forename: J
authors.initials: J
authors.lastname: Rosenman
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D004947:Esophagus / Q000473:pathology / Q000528:radiation effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage; D020266:Radiotherapy, Conformal; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D016190:Carboplatin; D017239:Paclitaxel; D000077235:Vinorelbine